乌帕替尼用于终末期肾病：一例急性重度溃疡性结肠炎病例
Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis.
作者信息
Hilley Patrick, Con Danny, Choy Matthew C, Srinivasan Ashish, De Cruz Peter
机构信息
Department of Gastroenterology Austin Health Heidelberg Victoria Australia.
Austin Academic Centre University of Melbourne Parkville Victoria Australia.
出版信息
JGH Open. 2023 Dec 13;7(12):1012-1015. doi: 10.1002/jgh3.13015. eCollection 2023 Dec.
Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal disease (ESRD), defined as an eGFR <15 mL/min/1.73m. Upadacitinib, a selective oral Janus kinase (JAK) 1 inhibitor, has demonstrated efficacy in the management of moderate to severe ulcerative colitis. There is also emerging data indicating that JAK inhibition may be clinically effective in the setting of steroid-refractory acute severe ulcerative colitis (ASUC). There is, however, a lack of "real-world" data documenting the use of JAK inhibitors in patients with ESRD. Here, we report the use of upadacitinib in a patient with ESRD for the management of steroid-refractory ASUC, demonstrating, for the first time, the safe and clinically effective use of upadacitinib in this population.
近期数据表明，炎症性肠病（IBD）可能是未来慢性肾脏病的一个风险因素，这凸显了研究晚期IBD疗法在终末期肾病（ESRD，定义为估算肾小球滤过率<15 mL/min/1.73m²）患者中的安全性和临床有效性的必要性。乌帕替尼是一种选择性口服Janus激酶（JAK）1抑制剂，已在中度至重度溃疡性结肠炎的治疗中显示出疗效。也有新出现的数据表明，JAK抑制在类固醇难治性急性重症溃疡性结肠炎（ASUC）的情况下可能具有临床疗效。然而，缺乏“真实世界”数据记录JAK抑制剂在ESRD患者中的使用情况。在此，我们报告了一名ESRD患者使用乌帕替尼治疗类固醇难治性ASUC的情况，首次证明了乌帕替尼在该人群中的安全且临床有效使用。
Zotero 插件